Anticoagulants Flashcards
indications for anticoagulant drugs
arterial disease (anti-platelets & anticoagulants)
- coronary artery disease
- cerebrovascular disease
- peripheral vascular disease
thromboembolic disease (anticoagulants)
- AF
- VTE
- prosthetic heart valves
mechanism of unfractionated heparin
- binds anti-thrombin 3 –> increases activity
- inactivates thrombin (IIa), Xa - requires APTT monitoring
- reversed with protamine
pharmacokinetics of UH
- must be given parenterally (IV or SC) CANT be absorbed
- rapid onset and offset
- varied molecular weight
adverse effects of UH
- bleeding = intracranial, injection sites, GI loss, epistaxis
- heparin-induced thrombocytopenia (autoimmune against platelets)
- osteoporosis (long-term)
LMWH
- smaller chains than UH
- binds to anti-thrombin III, doesn’t inactivate thrombin, instead specifically Xa
- lower risk of bleeding, HIT and osteoporosis
pharmacokinetics of LMWH (compared to UH)
- longer half-life
- more predictable dose-response relationship
- higher bioavailability
disadvantages of LMWH
- cant be monitored by APTT
- not fully reversible by protamine
- cleared by kidneys
indications for LMWH
- non-STEMI, STEMI
- initial treatment of VTE / PE
mechanism of warfarin
vitamin K antagonist
- inhibits synthesis of vitamin K dependent coagulation factors e.g. VII, IX, X, II
- slow onset of anticoagulant action due to turnover of circulating factors
indications for warfarin
tx of venous or arterial thrombosis
- VTE/PE
prevention of venous or arterial thromboembolism
- mechanical heart valves
- AF
warfarin metabolism
- crosses placenta (dont use in pregnancy)
- metabolised by CYP
- CYP450 inhibitors = higher INR
- CYP450 inducers = lower INR
adverse effects of warfarin
- haemorrhage (older people w/ previous bleeds)
- teratogenic
monitoring of warfarin
- titrate dose with INR
- checked every month
- various therapeutic ranges depending on cause
management of high INR
depends on the severity of the bleed
- IV vitamin K (slow onset, long duration)
- IV prothombinex
describe dabigatran
- warfarin alternative
- direct thrombin inhibitor
- renal excretion
- often used in patients with AF and VTE
- not CYP450 dependent